Caligan Partners LP
13F Reported Value
ⓘ$2.1B
incl. option notional
Equity Holdings
ⓘ$2.1B
Option Notional
ⓘ$53.0M
$0 puts / $53.0M calls
Holdings
28
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Caligan Partners LP disclosed 28 positions worth $2.1B in its Form 13F-HR for Q2 2026 — $2.1B in common stock plus $53.0M of put/call option positions (reported at underlying notional value, not premium at risk), led by $LQDA (Liquidia Corp) at 31.2% of the equity portfolio, followed by $RVMD and $ABVX. During the quarter the fund opened 5 new positions and exited 5 — including a new stake in $IMCR and a full exit from $MLYS. The portfolio is most concentrated in Healthcare (99.2% of disclosed assets). All figures are sourced directly from Caligan Partners LP’s Form 13F-HR filing with the SEC under CIK 1727492.
AI Fund Analysis
Concentrating
$LQDA
$RVMD
$ABVX
$EXEL
$AVTX$RVMD$AVTX
$ADMA
$AURA$ABVXSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 78.3#56
Quality
$647.3M8,118,892 sh - —
Quality
$367.4M1,961,795 sh - —
Quality
$207.6M1,557,924 sh - —
Quality
$127.2M2,188,636 sh - 76.2
Quality
$84.5M1,553,262 sh - 17.6
Quality
$78.2M2,500,103 sh - 11.7
Quality
$58.5M3,163,866 sh - 24.0
Quality
$53.7M889,944 sh - 69.7
Quality
$47.9M5,725,007 sh - $47.2M251,800 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| Liquidia Corp$LQDA | 78.3#56 | $647.3M | 8,118,892 |
| Revolution Medicines, Inc.$RVMD | — | $367.4M | 1,961,795 |
| Abivax S.A.$ABVX | — | $207.6M | 1,557,924 |
 Vaxcyte, Inc.$PCVX | — | $127.2M | 2,188,636 |
| EXELIXIS, INC.$EXEL | 76.2 | $84.5M | 1,553,262 |
 Tango Therapeutics, Inc.$TNGX | 17.6 | $78.2M | 2,500,103 |
| Avalo Therapeutics, Inc.$AVTX | 11.7 | $58.5M | 3,163,866 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $53.7M | 889,944 |
| ADMA BIOLOGICS, INC.$ADMA | 69.7 | $47.9M | 5,725,007 |
| Revolution Medicines, Inc.$RVMDCALL | — | $47.2M | 251,800 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Caligan Partners LP's 28 positions.
Showing top 10 of 28 holdings.
Sector Allocation
Healthcare
$2.1B
Other
$15.7M
Full Holdings — Caligan Partners LP (Q2 2026)
All 28 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $LQDA | Liquidia Corp | $647.3M | 31.2% | +0% | 78.3 |
| 2 | $RVMD | Revolution Medicines, Inc. | $367.4M | 17.7% | +19% | — |
| 3 | $ABVX | Abivax S.A. | $207.6M | 10.0% | +7% | — |
| 4 | $PCVX | Vaxcyte, Inc. | $127.2M | 6.1% | +6% | — |
| 5 | $EXEL | EXELIXIS, INC. | $84.5M | 4.1% | +0% | 76.2 |
| 6 | $TNGX | Tango Therapeutics, Inc. | $78.2M | 3.8% | +4% | 17.6 |
| 7 | $AVTX | Avalo Therapeutics, Inc. | $58.5M | 2.8% | +94% | 11.7 |
| 8 | $XENE | Xenon Pharmaceuticals Inc. | $53.7M | 2.6% | -36% | 24 |
| 9 | $ADMA | ADMA BIOLOGICS, INC. | $47.9M | 2.3% | +20% | 69.7 |
| 10 | $RVMDCALL | Revolution Medicines, Inc. | $47.2M | — | +10% | — |
| 11 |  $LBRX | LB PHARMACEUTICALS INC | $46.7M | 2.3% | +0% | — |
| 12 |  $IMCR | Immunocore Holdings plc | $43.9M | 2.1% | NEW | — |
| 13 |  $VRDN | Viridian Therapeutics, Inc.\DE | $40.3M | 1.9% | NEW | 27.2 |
| 14 |  $VOR | Vor Biopharma Inc. | $35.4M | 1.7% | +0% | — |
| 15 |  $SABS | SAB Biotherapeutics, Inc. | $31.1M | 1.5% | +0% | — |
| 16 |  $IVA | Inventiva S.A. | $30.9M | 1.5% | +64% | — |
| 17 | $AURA | Aura Biosciences, Inc. | $30.5M | 1.5% | +1770% | — |
| 18 |  $TYRA | Tyra Biosciences, Inc. | $25.8M | 1.2% | -37% | — |
| 19 |  $IRD | Opus Genetics, Inc. | $25.0M | 1.2% | +0% | — |
| 20 |  $ANIK | Anika Therapeutics, Inc. | $21.0M | 1.0% | +0% | 34.4 |
| 21 |  $SGMT | Sagimet Biosciences Inc. | $19.3M | 0.9% | NEW | — |
| 22 |  $ARTV | Artiva Biotherapeutics, Inc. | $16.8M | 0.8% | NEW | 9.7 |
| 23 | — | FAETH THERAPEUTICS INC - COM NEW | $15.7M | 0.8% | +400% | — |
| 24 |  $MBX | MBX Biosciences, Inc. | $11.0M | 0.5% | -76% | — |
| 25 |  $VRCA | Verrica Pharmaceuticals Inc. | $5.7M | 0.3% | +0% | 32.7 |
| 26 |  $AGIOCALL | AGIOS PHARMACEUTICALS, INC. | $3.3M | — | +0% | 26.9 |
| 27 | $ADMACALL | ADMA BIOLOGICS, INC. | $2.5M | — | +0% | 69.7 |
| 28 |  $CLRB | Cellectar Biosciences, Inc. | $1.3M | 0.1% | NEW | — |
New Positions (5)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Caligan Partners LP including:
Track Caligan Partners LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Caligan Partners LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Caligan Partners LP
13F Pro is an AI hedge fund tracker and stock research platform. For Caligan Partners LP (SEC CIK: 1727492), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Caligan Partners LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.